Cargando…
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
BACKGROUND: The emergence of immune-escape variants of severe acute respiratory syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019. METHODS: In an ongoing phase 3 trial, adults older than 55 years who had previously received th...
Autores principales: | Winokur, Patricia, Gayed, Juleen, Fitz-Patrick, David, Thomas, Stephen J., Diya, Oyeniyi, Lockhart, Stephen, Xu, Xia, Zhang, Ying, Bangad, Vishva, Schwartz, Howard I., Denham, Douglas, Cardona, Jose F., Usdan, Lisa, Ginis, John, Mensa, Federico J., Zou, Jing, Xie, Xuping, Shi, Pei-Yong, Lu, Claire, Buitrago, Sandra, Scully, Ingrid L., Cooper, David, Koury, Kenneth, Jansen, Kathrin U., Türeci, Özlem, Şahin, Uğur, Swanson, Kena A., Gruber, William C., Kitchin, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933930/ https://www.ncbi.nlm.nih.gov/pubmed/36652353 http://dx.doi.org/10.1056/NEJMoa2213082 |
Ejemplares similares
-
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023) -
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021) -
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023) -
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022) -
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022)